(Q28266580)

1

0 references

Takeshi Ishikawa

2

0 references

Satoshi Kokura

3

0 references

Tetsuya Okayama

4

0 references

Kaname Oka

5

0 references

Mitsuko Ideno

6

0 references

Fumiyo Sakai

7

0 references

Akiko Kato

8

0 references

Masashige Tanabe

9

0 references

Tatsuji Enoki

10

0 references

Junichi Mineno

11

0 references

Yuji Naito

12

0 references

Yoshito Itoh

Journal of Translational Medicine

13

0 references

language of work or name

English

0 references

publication date

25 August 2015

0 references

published in

0 references

volume

13

0 references

issue

1

0 references

page(s)

277

0 references

cites work

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

A new class of membrane-bound chemokine with a CX3C motif

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Innate or adaptive immunity? The example of natural killer cells

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Adoptive therapy using antigen-specific T-cell clones

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Natural killer cell-based immunotherapy in cancer: current insights and future prospects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Prospects for the use of NK cells in immunotherapy of human cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Large-scale generation of natural killer lymphocytes for clinical application

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

A potential role for interleukin-15 in the regulation of human natural killer cell survival

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548900

Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?

2 June 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0632-8

Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0632-8

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0632-8

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0632-8

Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0632-8

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer

21 January 2018

1 reference

12 December 2020

Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer

1 reference

12 December 2020

Exposing tumor cells to killer cell attack

1 reference

12 December 2020

A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells

1 reference

12 December 2020

A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells

1 reference

12 December 2020

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

1 reference

12 December 2020

Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic

1 reference

12 December 2020

10.1186/S12967-015-0632-8

Identifiers

DOI

1 reference

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s12967-015-0632-8

1 reference

1 reference

PubMed publication ID

26303618

1 reference